2014
DOI: 10.1128/cvi.00696-13
|View full text |Cite
|
Sign up to set email alerts
|

Inclusion of the Bovine Neutrophil Beta-Defensin 3 with Glycoprotein D of Bovine Herpesvirus 1 in a DNA Vaccine Modulates Immune Responses of Mice and Cattle

Abstract: Bovine herpesvirus 1 (BoHV-1) causes recurrent respiratory and genital infections in cattle and predisposes them to lethal secondary infections. While modified live and killed BoHV-1 vaccines exist, these are not without problems. Development of an effective DNA vaccine for BoHV-1 has the potential to address these issues. As a strategy to enhance DNA vaccine immunity, a plasmid encoding the bovine neutrophil beta-defensin 3 (BNBD3) as a fusion with truncated glycoprotein D (tgD) and a mix of two plasmids enco… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
17
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 20 publications
(17 citation statements)
references
References 79 publications
(96 reference statements)
0
17
0
Order By: Relevance
“…In terms of β-defensins, human β-defensin (HBD) 3 and a synthetic β-defensin analog constituted by domains of HBD-1 and HBD-3 have been confirmed to inactivate HSV [20,25,26]. Bovine neutrophil β-defensin 3 has been found to show inhibitory activity against bovine herpes virus 1 [27,28]. Besides, HBD-2 has been reported to inhibit varicella zoster virus infection [29].…”
Section: Introductionmentioning
confidence: 99%
“…In terms of β-defensins, human β-defensin (HBD) 3 and a synthetic β-defensin analog constituted by domains of HBD-1 and HBD-3 have been confirmed to inactivate HSV [20,25,26]. Bovine neutrophil β-defensin 3 has been found to show inhibitory activity against bovine herpes virus 1 [27,28]. Besides, HBD-2 has been reported to inhibit varicella zoster virus infection [29].…”
Section: Introductionmentioning
confidence: 99%
“…In our quest for this ideal vaccine, we previously studied the immune response-enhancing capacity of BNBD3 (34) in a DNA vaccine as a fusion construct with tgD of BoHV-1. This vaccination strategy increased cell-mediated immune responses, including the induction of CTLs, and was protective against BoHV-1, but these improvements did not result in improved clinical responses, compared to the DNA vaccine encoding tgD alone, which could have been because the vaccine did not concurrently increase humoral responses (22). We then hypothesized that the same cationic peptide, BNBD3, might improve the humoral responses without loss of robust CMI responses if it was formulated in a complex with pMASIA-tgD.…”
Section: Discussionmentioning
confidence: 99%
“…Following overnight incubation at 4°C, the plates were washed, and bound IgG1 and IgG2a were detected using biotinylated goat anti-mouse IgG1 and IgG2a antibodies (Caltag Laboratories, Burlingame, CA, USA) for 1 h at RT followed by streptavidin-alkaline phosphatase (AP) for 1 h at RT. Bound IgG was detected as described previously (22). All reactions were visualized with 0.01 M p-nitrophenyl phosphate (PNPP) (Sigma-Aldrich), and absorbance was read at 405 nm.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations